Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 126

Similar articles for PubMed (Select 23228984)

1.

Phase I study of bevacizumab combined with irinotecan and S-1 as second-line chemotherapy in patients with advanced colorectal cancer.

Kusaba H, Esaki T, Kishimoto J, Uchino K, Arita S, Kumagai H, Mitsugi K, Akashi K, Baba E.

Cancer Chemother Pharmacol. 2013 Jan;71(1):29-34. doi: 10.1007/s00280-012-2023-7. Epub 2012 Dec 11.

PMID:
23228984
2.

Prevention of irinotecan induced diarrhea by probiotics: A randomized double blind, placebo controlled pilot study.

Mego M, Chovanec J, Vochyanova-Andrezalova I, Konkolovsky P, Mikulova M, Reckova M, Miskovska V, Bystricky B, Beniak J, Medvecova L, Lagin A, Svetlovska D, Spanik S, Zajac V, Mardiak J, Drgona L.

Complement Ther Med. 2015 Jun;23(3):356-62. doi: 10.1016/j.ctim.2015.03.008. Epub 2015 Apr 4.

PMID:
26051570
3.

A Phase II study of S-1 and irinotecan combination therapy in previously treated patients with advanced non-small cell lung cancer.

Ikemura S, Naoki K, Yasuda H, Kawada I, Yoda S, Terai H, Sato T, Ishioka K, Arai D, Ohgino K, Kamata H, Miyata J, Kabata H, Betsuyaku T, Soejima K.

Jpn J Clin Oncol. 2015 Apr;45(4):356-61. doi: 10.1093/jjco/hyu226. Epub 2015 Jan 22.

PMID:
25612761
4.

[Study of S-1 and oxaliplatin(SOX) plus bevacizumab as first-line therapy in patients with unresectable colorectal cancer].

Maruo H, Suzuki K, Ishikawa S, Murakami T, Higashi Y, Shoji T, Yamazaki M, Taniguchi M, Nishiyama R.

Gan To Kagaku Ryoho. 2014 Dec;41(13):2583-6. Japanese.

PMID:
25596052
5.

A Phase II Trial of Combined Chemotherapy with Oral S-1 and 24-Hour Infusions of Irinotecan plus Bevacizumab in Patients with Metastatic Colorectal Cancer.

Sadahiro S, Suzuki T, Tanaka A, Okada K, Saito G, Kamijo A.

Oncology. 2015;88(6):353-9. doi: 10.1159/000369976. Epub 2015 Jan 9.

6.

Efficacy and safety of irinotecan plus S-1 (IRIS) therapy to treat advanced/recurrent colorectal cancer.

Higashi D, Egawa Y, Hirano Y, Hirano K, Miyake T, Takahashi H, Uwatoko S, Abe S, Yamamoto S, Mikami K, Futami K, Maekawa T, Inoue R, Miyazaki M.

Anticancer Res. 2014 Aug;34(8):4595-9.

PMID:
25075105
7.

Efficacy of S-1 in colorectal cancer.

Miyamoto Y, Sakamoto Y, Yoshida N, Baba H.

Expert Opin Pharmacother. 2014 Aug;15(12):1761-70. doi: 10.1517/14656566.2014.937706. Review.

PMID:
25032886
8.

Phase I/II trial of irinotecan and S-1 combination chemotherapy as a second-line treatment for advanced colorectal cancer.

Takii Y, Yamazaki T, Okada T, Tani T, Funakoshi K, Maruyama S, Hasegawa J, Akazawa K, Hatakeyama K; Niigata Colorectal cancer Chemotherapy Study Group.

Chemotherapy. 2013;59(5):338-43. doi: 10.1159/000358482. Epub 2014 May 9.

PMID:
24820531
9.

Exploring better strategies for EGFR antibodies in colon cancer.

Cervantes A.

Lancet Oncol. 2014 May;15(6):549-50. doi: 10.1016/S1470-2045(14)70137-8. Epub 2014 Apr 3. No abstract available.

10.

Phase 1/2 study of KRN330, a fully human anti-A33 monoclonal antibody, plus irinotecan as second-line treatment for patients with metastatic colorectal cancer.

Bendell JC, Lenz HJ, Ryan T, El-Rayes BF, Marshall JL, Modiano MR, Hart LL, Kingsley CD, George TJ, Nakashima D, Berlin JD.

Invest New Drugs. 2014 Aug;32(4):682-90. doi: 10.1007/s10637-014-0088-3. Epub 2014 Apr 3.

PMID:
24691674
11.

Phase I study of anti-VEGF monoclonal antibody bevacizumab and histone deacetylase inhibitor valproic acid in patients with advanced cancers.

Wheler JJ, Janku F, Falchook GS, Jackson TL, Fu S, Naing A, Tsimberidou AM, Moulder SL, Hong DS, Yang H, Piha-Paul SA, Atkins JT, Garcia-Manero G, Kurzrock R.

Cancer Chemother Pharmacol. 2014 Mar;73(3):495-501. doi: 10.1007/s00280-014-2384-1. Epub 2014 Jan 17.

13.

A phase II study of combined chemotherapy with 5-week cycles of S-1 and CPT-11 plus bevacizumab in patients with metastatic colon cancer.

Mizushima T, Ide Y, Murata K, Ohashi I, Yasumasa K, Fukunaga M, Takemoto H, Tamagawa H, Hasegawa J, Hata T, Takemasa I, Ikeda M, Yamamoto H, Sekimoto M, Nezu R, Doki Y, Mori M.

Oncology. 2013;85(6):317-22. doi: 10.1159/000356018. Epub 2013 Nov 12.

PMID:
24247419
14.

S-1: another oral agent for patients with colorectal cancer.

Benson AB 3rd.

Lancet Oncol. 2013 Dec;14(13):1244-5. doi: 10.1016/S1470-2045(13)70533-3. Epub 2013 Nov 11. No abstract available.

PMID:
24225156
15.

[Continuation of chemotherapy with bevacizumab for advanced and recurrent colorectal cancer].

Soga Y, Ito D, Asano H, Go M, Iwai M, Okada K, Matsuoka T, Adachi S, Usami E, Kimura M, Nakao T, Yoshimura T, Yasuda T, Ogawa T, Iwaki A.

Gan To Kagaku Ryoho. 2013 Oct;40(10):1341-5. Japanese.

PMID:
24105057
16.

A phase 1 trial of imatinib, bevacizumab, and metronomic cyclophosphamide in advanced colorectal cancer.

Kelley RK, Hwang J, Magbanua MJ, Watt L, Beumer JH, Christner SM, Baruchel S, Wu B, Fong L, Yeh BM, Moore AP, Ko AH, Korn WM, Rajpal S, Park JW, Tempero MA, Venook AP, Bergsland EK.

Br J Cancer. 2013 Oct 1;109(7):1725-34. doi: 10.1038/bjc.2013.553. Epub 2013 Sep 10.

17.

Phase I clinical and pharmacokinetic/pharmacogenetic study of a triplet regimen of S-1/irinotecan/oxaliplatin in patients with metastatic colorectal or gastric cancer.

Park SR, Hong YS, Lim HS, Seong MW, Kong SY, Kim SY, Park YI, Jung KH.

Cancer Chemother Pharmacol. 2013 Nov;72(5):953-64. doi: 10.1007/s00280-013-2272-0. Epub 2013 Aug 28.

PMID:
23982118
18.

S-1 plus irinotecan and oxaliplatin for the first-line treatment of patients with metastatic colorectal cancer: a prospective phase II study and pharmacogenetic analysis.

Kim SY, S Hong Y, K Shim E, Kong SY, Shin A, Baek JY, Jung KH.

Br J Cancer. 2013 Sep 17;109(6):1420-7. doi: 10.1038/bjc.2013.479. Epub 2013 Aug 20.

19.

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).

Middleton G, Brown S, Lowe C, Maughan T, Gwyther S, Oliver A, Richman S, Blake D, Napp V, Marshall H, Wadsley J, Maisey N, Chau I, Hill M, Gollins S, Myint S, Slater S, Wagstaff J, Bridgewater J, Seymour M.

Eur J Cancer. 2013 Nov;49(16):3507-16. doi: 10.1016/j.ejca.2013.06.017. Epub 2013 Aug 13.

PMID:
23953030
20.

Phase 1 pharmacokinetic study of MK-0646 (dalotuzumab), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in combination with cetuximab and irinotecan in Japanese patients with advanced colorectal cancer.

Doi T, Muro K, Yoshino T, Fuse N, Ura T, Takahari D, Feng HP, Shimamoto T, Noguchi K, Ohtsu A.

Cancer Chemother Pharmacol. 2013 Sep;72(3):643-52. doi: 10.1007/s00280-013-2240-8. Epub 2013 Aug 7.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk